Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth (2009)
MPG-8/Chol-MPG-8 (15% Chol coating)
Sequence: Chol-bAFLGWLGAWGTMGWSPKKKRK-Cya
| Experiment Id | EXP000169 |
|---|---|
| Paper | Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth |
| Peptide | MPG-8/Chol-MPG-8 (15% Chol coating) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 5–10 µg siRNA (0.25–0.5 mg/kg) |
| Mixing Ratio | 20:1 MPG-8:siRNA + 15% Chol-MPG-8 |
| Formulation Format | MPG-8/siRNA (20:1) coated with Chol-MPG-8 (15%) for systemic delivery |
| Formulation Components | |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | PC3 xenograft nude mice; SKBr3-HER2 xenograft nude mice |
| Administration Route | intravenous |
| Output Type | tumor growth inhibition / survival |
| Output Value | PC3: 60% (5 µg) and 92% (10 µg) inhibition; SKBr3-HER2: survival benefit (70% at day 40) |
| Output Units | |
| Output Notes | |
| Toxicity Notes | |
| Curation Notes |